Neurological research · 2025
Enhanced expression of miR-128 in peripheral blood mononuclear cells: a potent candidate diagnostic biomarker for multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akhgari Hossein, Ahmadi Alireza, Rezaei Abedeh, Mohammadi Ali, Safaralizadeh Reza
Аннотация
OBJECTIVES: Millions of people worldwide, especially young adults, are affected by multiple sclerosis (MS), a demyelinating and autoimmune condition of the central nervous system (CNS). Many studies have focused on the diagnostic value of miRNAs circulating in body fluids of MS patients. Thus, this study aimed to assess the expression of miR-128 and its potential as a biomarker for MS in the Iranian population.
METHODS: This study recruited 85 MS patients and 30 healthy matched controls. Following the collection of blood samples, serum was isolated. RNA was then extracted, cDNA was synthesized, and miR-128 expression was measured by real-time PCR.
RESULTS: There was significant overexpression of miR-128 in MS patients in comparison with healthy controls (p-value <0.0001). In addition, there was a rather notable association between the subtypes of MS samples and the expression levels of miR-128. ROC analysis showed an AUC of 0.9111 (95%CI 0.85-0.97, p-value <0.0001) with sensitivity and specificity of 80.00% and 93.33%, respectively.
CONCLUSION: The expression of miR-128 was significantly higher in PBMCs of MS patients in comparison with healthy controls. Additionally, miR-128 could be an excellent biomarker for MS patient diagnosis.
METHODS: This study recruited 85 MS patients and 30 healthy matched controls. Following the collection of blood samples, serum was isolated. RNA was then extracted, cDNA was synthesized, and miR-128 expression was measured by real-time PCR.
RESULTS: There was significant overexpression of miR-128 in MS patients in comparison with healthy controls (p-value <0.0001). In addition, there was a rather notable association between the subtypes of MS samples and the expression levels of miR-128. ROC analysis showed an AUC of 0.9111 (95%CI 0.85-0.97, p-value <0.0001) with sensitivity and specificity of 80.00% and 93.33%, respectively.
CONCLUSION: The expression of miR-128 was significantly higher in PBMCs of MS patients in comparison with healthy controls. Additionally, miR-128 could be an excellent biomarker for MS patient diagnosis.